Highlights
• Neuren Pharmaceuticals shares rose 6.30% to AUD 13.08 on 8 April 2026 following a key product update
• The stock is now up 40.74% over the past year, reflecting sustained investor confidence
• DAYBUE STIX is now broadly available in the United States for Rett syndrome treatment
• More than 80% of early users reported satisfaction during the initial limited launch phase
• New formulation offers improved flexibility and portability for caregivers and patients

Neuren Pharmaceuticals Ltd (ASX:NEU) shares climbed 6.30% to AUD 13.08 during the morning session on 8 April 2026, extending its favourable momentum with gains of 40.74% over the past year.

Today’s upward move follows the company’s announcement that its partner Acadia Pharmaceuticals has expanded the availability of DAYBUE STIX (trofinetide) across the United States, marking a significant step in improving treatment accessibility for Rett syndrome patients.

Expanded US Access Supports Growth Narrative

The latest update confirms that DAYBUE STIX, a powder formulation of trofinetide for oral solution, is now broadly available in the US. This follows its approval by the US Food and Drug Administration in December 2025 and a controlled initial rollout during the first quarter of 2026.

The broader commercial availability represents a key milestone, as it transitions the product from a limited launch phase into wider distribution. This expansion is expected to enhance accessibility for both adult and pediatric patients aged two years and older diagnosed with Rett syndrome.

The formulation has been specifically designed to improve ease of administration. Caregivers can mix the powder with a variety of water-based liquids, including juice, tea, lemonade, or hydration drinks, allowing for a more tailored approach to patient preferences. Additionally, the product is supplied in individual packets, making it portable and convenient for daily use.

Early Feedback Highlights Strong User Acceptance

Initial feedback gathered during the limited launch phase indicates a positive reception among caregivers. According to Acadia Pharmaceuticals, more than 80% of early users reported satisfaction with DAYBUE STIX.

This high satisfaction rate underscores the importance of flexibility in treatment delivery, particularly for conditions like Rett syndrome where patient needs can vary significantly. The ability to customise administration based on taste and convenience appears to be a key differentiator for the product.

The strong early response may also support broader adoption as the product becomes more widely available, reinforcing the commercial potential of the new formulation.

Clinical Community Reinforces Role of Trofinetide

The announcement also highlighted recent expert recommendations regarding the real-world use of trofinetide in Rett syndrome management. A steering group comprising specialists from International Rett Syndrome Foundation-designated centres of excellence reached a consensus recognising trofinetide oral solution as part of the standard of care.

The group emphasised several important considerations, including early initiation of treatment and continued use over time to optimise patient outcomes. The recommendations also stress the need for personalised treatment decisions, reflecting the complex and individualised nature of Rett syndrome care.

Medical professionals have also pointed to the benefits of the new formulation in clinical practice. The availability of an alternative method of administration provides additional flexibility, enabling healthcare providers and caregivers to better address specific patient needs.

Patient-Centric Innovation Drives Treatment Evolution

The introduction of DAYBUE STIX reflects a broader shift towards patient-centred treatment approaches in neurological disorders. By offering a formulation that prioritises convenience, adaptability, and ease of use, the product aligns with evolving expectations in both clinical and home-care settings.

The ability to integrate treatment into daily routines more seamlessly can play a critical role in long-term adherence, particularly in paediatric populations. The portable, customisable nature of the formulation further supports its practical application in real-world scenarios.

This focus on usability, combined with clinical validation and regulatory approval, positions the product as an important advancement in the management of Rett syndrome.

Company Overview and Pipeline Progress

Neuren Pharmaceuticals is focused on developing therapies for serious neurological disorders linked to genetic abnormalities or brain injury, particularly where treatment options remain limited or unavailable. The company’s research is centred on targeting the role of Insulin-like Growth Factor 1 (IGF-1) in brain function, using orally administered analogues of naturally occurring peptides.

DAYBUE (trofinetide) oral solution has already received regulatory approvals in multiple regions, including the United States, Canada, and Israel. Neuren has granted Acadia Pharmaceuticals exclusive global rights for the development and commercialisation of trofinetide.

Beyond DAYBUE, Neuren is advancing its second drug candidate, NNZ-2591, which is being developed as an oral treatment for several neurodevelopmental disorders. The candidate has delivered positive Phase 2 trial results in conditions such as Phelan-McDermid syndrome, Pitt Hopkins syndrome, and Angelman syndrome.

These programs have received multiple regulatory designations, including orphan drug status in both the United States and the European Union, as well as Fast Track and Rare Pediatric Disease designations from the FDA. Such designations highlight the potential significance of these therapies in addressing unmet medical needs.

The company is also progressing a Phase 3 clinical trial, known as “Koala,” evaluating NNZ-2591 in children aged 3 to 12 years with Phelan-McDermid syndrome, alongside a long-term extension study.

What This Means for Investors?

The latest update signals continued commercial progress for Neuren Pharmaceuticals, with the expanded US availability of DAYBUE STIX representing a meaningful step forward in product adoption. The strong early user feedback, combined with clinical endorsement and regulatory backing, reinforces confidence in the therapy’s role within Rett syndrome treatment.

Today’s share price increase suggests that investors are responding positively to the transition from limited launch to broader market access, viewing it as a catalyst for potential revenue growth. With the stock already up 40.74% over the past year, the development adds further support to the company’s growth trajectory.

As commercial rollout continues and pipeline programs advance, market participants are likely to remain focused on execution, adoption rates, and ongoing clinical progress across Neuren’s portfolio.